Related Experiment Video
Updated: Jul 16, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Drug evaluation: DNA/MVA prime-boost HIV vaccine
Stephen Kent1, Robert De Rose, Erik Rollman
1University of Melbourne, Department of Microbiology and Immunology, Melbourne, Victoria 3010, Australia. skent@unimelb.edu.au
Abstract:
Oxford University and Nairobi University are jointly developing a HIVA.DNA/modified vaccinia Ankara (MVA) prime-boost vaccine for the potential prevention of infection with HIV subtype A. The vaccination strategy consists of priming with a DNA vaccine made from HIV-1 clade A gag p24/p17 consensus sequence (pTHr.HIVA) then boosting with a MVA virus expressing HIVA (MVA.HIVA). Phase II clinical trials of the vaccine are underway in Kenya and the UK.
